Skip to main content

Advertisement

Table 3 Effect of azithromycin on changes in sTNFR75 levels at 3 months according to subgroups

From: Azithromycin and risk of COPD exacerbations in patients with and without Helicobacter pylori

Subgroup   sTNFR75 level (μg/L) p-value*
N Baseline 3 months Difference
HP + 76 8.65 ± 0.50 7.78 ± 0.45 −0.87 ± 0.31 0.002
HP - 356 8.52 ± 0.24 8.63 ± 0.32 0.11 ± 0.25 0.64
Total 432 8.54 ± 0.22 8.48 ± 0.27 −0.06 ± 0.21 0.10
Ex-smoker 360 8.73 ± 0.24 8.56 ± 0.31 −0.17 ± 0.24 0.03
Smoker 89 8.10 ± 0.41 8.11 ± 0.43 0.01 ± 0.30 0.89
Age > 65 220 8.52 ± 0.29 8.46 ± 0.42 −0.06 ± 0.36 0.25
Age ≤ 65 229 8.68 ± 0.31 8.48 ± 0.32 −0.20 ± 0.20 0.08
GOLD 2 120 9.07 ± 0.39 9.08 ± 0.67 0.01 ± 0.60 0.15
GOLD 3 183 8.68 ± 0.32 8.49 ± 0.34 −0.19 ± 0.22 0.29
GOLD 4 145 8.12 ± 0.40 7.86 ± 0.40 −0.26 ± 0.27 0.19
  1. Data are presented as means ± standard errors of the mean
  2. sTNFR75 soluble tumor necrosis factor-75, GOLD Global Initiative for Chronic Obstructive Lung Disease, HP Helicobacter pylori
  3. *Paired t-tests on log-transformed data